Elevation Oncology Inc (NASDAQ:ELEV) price on current trading day, rose 11.59% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.26.
A look at the stock’s price movement, the close in the last trading session was $0.23, moving within a range at $0.2232 and $0.26. The beta value (5-Year monthly) was 1.668. Turning to its 52-week performance, $4.98 and $0.23 were the 52-week high and 52-week low respectively. Overall, ELEV moved -47.38% over the past month.
Elevation Oncology Inc’s market cap currently stands at around $15.40 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-05.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ELEV is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend ELEV as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ELEV’s current price about -19.59% and -46.18% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 31.34, while 7-day volatility ratio is 11.29% and 10.99% in the 30-day chart. Further, Elevation Oncology Inc (ELEV) has a beta value of 1.60, and an average true range (ATR) of 0.04. Analysts have given the company’s stock an average 52-week price target of $9, forecast between a low of $8 and high of $10. Looking at the price targets, the low is -2976.92% off current price level while to achieve the yearly target high, price needs to move -3746.15%. Nonetheless, investors will most likely welcome a -3361.54% jump to $9 which is the analysts’ median price.
If we refocus on Elevation Oncology Inc (NASDAQ:ELEV), historical trading data shows that trading volumes averaged 1.25 over the past 10 days and 2.41 million over the past 3 months. The company’s latest data on shares outstanding shows there are 59.13 million shares.
The 12.09% of Elevation Oncology Inc’s shares are in the hands of company insiders while institutional holders own 65.96% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.75 million on 2025-03-14, giving us a short ratio of 9.19. The data shows that as of 2025-03-14 short interest in Elevation Oncology Inc (ELEV) stood at 1560.9999 of shares outstanding, with shares short falling to 8.79 million registered in 2025-02-14. Current price change has pushed the stock -53.79% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ELEV stock continues to rise going into the next quarter.
